At Otsuka, our dedication to patients, families, and providers drives us to uncover answers to complex, underserved medical needs. Collaborations are an essential part of this commitment, and we seek to work with companies whose values, commitment, and compassion align with our own.
When working together in alliances or as affiliates, our OAPI Global Strategic Alliance Management team strives to create a culture of empathy and creativity that is rooted in our dedication to 3 areas of focus: neuroscience, nephrology, and digital innovation. They provide the tools and leadership to enable each relationship to reach its maximum value and potential, and are committed to:
Develop relationships with collaborators built on trust.
Realize and maximize the spirit and intent of each unique collaboration.
Use a proven, disciplined approach to ensure that collaborations balance rigor and flexibility to support timely decision-making, early detection and mitigation of risk, and effective conflict resolution.
Many pharmaceutical companies have experienced challenges when ushering in new central nervous system (CNS) treatments. The Otsuka and Lundbeck global alliance agreement was born in 2011 out of this challenge. Both companies have a shared focus on helping patients with mental health disorders. Lundbeck has a long heritage of innovation in neuroscience, and Otsuka has been focusing research and development efforts on CNS for decades. Through this alliance, Otsuka and Lundbeck have taken an unconventional approach to develop and commercialize 5 psychiatric and neurologic therapies worldwide thus far. Together we are creating a positive impact to help improve the lives of people living with CNS disorders.
Akebia Therapeutics Inc, is a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease. Otsuka and Akebia entered into an alliance agreement in 2016 to support the development of and the commercialization of vadadustat. Vadadustat is an investigational drug in a new class of oral hypoxia-inducible factor (HIF) stabilizers, and is currently in development as a potential treatment for anemia associated with chronic kidney disease (CKD). With Otsuka’s long-standing commitment to the nephrology category and Akebia’s focus on delivering innovative therapies, both companies are contributing to changing the standard of care for patients with CKD.
With Otsuka’s focus on digital innovation and unconventional thinking, our alliance with Click Therapeutics is a natural step toward developing solutions for patients that go beyond medication. We are working on developing and commercializing a prescription digital therapeutic for treating major depressive disorder (MDD). This alliance combines Click Therapeutics’ specialization in discovering, validating, and deploying software applications with Otsuka’s commitment and expertise in researching, developing, and commercializing treatments for mental illness. Together, we are breaking down barriers and have the potential to help transform mental healthcare.
There is a great need for novel medicines in the area of neuropsychiatric medicine development. The global collaboration agreement between Sunovion (together with its parent company Sumitomo Dainippon Pharma Co., Ltd.) and Otsuka is focused on working on collaborative solutions to address these areas of unmet medical need, and will invest in advancing promising compounds while leveraging their complementary therapeutic area expertise. The goal of these co-development programs is to contribute to changing the course of serious medical conditions and provide new treatment options to patients and healthcare providers globally.
Avanir Pharmaceuticals is at the forefront of researching and developing ground-breaking treatments for CNS conditions in areas of unmet need to improve the lives of patients and their care communities. As part of the Otsuka family, Avanir will continue to push the boundaries of science to provide clinical solutions that alleviate the burdens of those affected by CNS conditions like Alzheimer's disease and Parkinson's disease.
Our commitment to neuroscience is strengthened by our affiliation with Astex Pharmaceuticals. Astex is a leader in therapeutic discovery and development and is committed to fighting both cancer and CNS disorders. Astex operates two sites, one in the United Kingdom and one in the United States. The United Kingdom serves as headquarters for clinical development and research. The US-based site, located in California, is focused on product development and commercialization. With complementary research and development strengths, there is significantly greater potential to bring forth new therapies in neuroscience and oncology than was previously possible.
Otsuka acquired Visterra in 2018 to continue developing solutions for unmet needs in nephrology. Visterra is a clinical-stage biotechnology company that is committed to developing innovative antibody-based therapies for patients with kidney diseases and other hard-to-treat conditions. The Visterra pipeline includes programs targeting immunoglobulin A nephropathy and kidney diseases, as well as cancer, chronic pain, and infectious diseases. The extensive overlap in therapeutic focus between our two companies, along with a shared culture of creativity and commitment to patients, enables us to tackle the most difficult treatment challenges.
McQuade Center for Strategic Research & Development (MSRD)
The McQuade Center for Strategic Research and Development (MSRD) is a US limited-liability company that was started to identify and fund innovative early-stage research and development programs. These programs are the building blocks for future Otsuka products. MSRD is named for Robert McQuade, PhD, who is the Executive Vice-President, Chief Strategic Officer for Otsuka in the US and President of this organization.
Let’s explore how we can work together to improve the lives of patients.